henhaobio
Sign in

bioRxivCancer BiologyPreprint

Integrin beta4 promotes DNA damage drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/Rac1

H. Fang, W. Ren, Q. Cui, H. Liang, C. Yang, W. Liu, X. Wang, X. Liu, Y. Shi, J. Feng, C. Chen

PDFDOI

Abstract

Anti-tumor drug resistance is a challenge for human triple-negative breast cancer treatment. Our previous work demonstrated that TNFAIP2 activates RAC1 to promote triple-negative breast cancer cell proliferation and migration. However, the mechanism by which TNFAIP2 activates RAC1 is unknown. In this study, we found that TNFAIP2 interacts with IQGAP1 and Integrin {beta}4. Integrin {beta}4 activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in triple-negative breast cancer. These results indicate that the Integrin {beta}4/TNFAIP2/IQGAP1/RAC1 axis provides potential therapeutic targets to overcome DNA damage-related drug resistance in triple-negative breast cancer.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Related papers

Similarity Map
SelectedSame fieldCross-field
THISOliveira '21He '26Parveen '20Chen '19Yedier-Bayr '25Sriramulu '24
70% semantic matchCancer Biology
W. A. Abreu de Oliveira, S. Moens, Y. El Laithy+9 more·bioRxiv·May 21, 2021